C.R. Bard's Q1 profits plunge on $26M in transvaginal mesh legal fees
April 24, 2013 by Brad Perriello
Profits plunge for medical device company C.R. Bard during the 1st quarter, largely due to a nearly $26 million charge stemming from lawsuits filed over its transvaginal mesh products.
C.R. Bard (NYSE:BCR) saw its 1st-quarter profits plunge on a nearly $26 million charge stemming from the bevy of lawsuits filed against it over its transvaginal mesh products.
But the Murray Hill, N.J.-based medical device company still managed to exceed Wall Street's expectations with its adjusted earnings, leading investors to keep BCR shares about flat today in mid-morning trading.
April 24, 2013 by Brad Perriello
Profits plunge for medical device company C.R. Bard during the 1st quarter, largely due to a nearly $26 million charge stemming from lawsuits filed over its transvaginal mesh products.
C.R. Bard (NYSE:BCR) saw its 1st-quarter profits plunge on a nearly $26 million charge stemming from the bevy of lawsuits filed against it over its transvaginal mesh products.
But the Murray Hill, N.J.-based medical device company still managed to exceed Wall Street's expectations with its adjusted earnings, leading investors to keep BCR shares about flat today in mid-morning trading.